NCT06448273

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects

Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic Characteristics of Single and Multiple Doses of TQB3702 Tablets in Healthy Adult Subjects

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a phase I, randomized, double-blind, placebo-controlled, dose-escalating clinical study aimed at evaluating the safety of TQB3702 tablets following single and multiple doses administered to healthy subjects

Conditions

• Systemic Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	TQB3702 tablets	TQB3702 tablets is administered as a single dose on day 1, or once daily on Days 1 to 7 on multiple dose. Dosage: 100mg, 150/200mg.
DRUG	TQB3702 placebo	TQB3702 placebo contains no active substance.

Timeline

• Start date: 2024-07-19
• Primary completion: 2024-10-01
• Completion: 2024-10-01
• First posted: 2024-06-07
• Last updated: 2024-08-12

Locations

1 site across 1 country: China